READ-ONLY DIGITIZATION RESULT
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.
Nat Commun · 2026-Mar-14 · PMID 41826281
Panel B提取失败待 EXE 对齐验证
Progression-free survival
Fig. 4. Progression-free survival by PD-L1 expression. Kaplan–Meier estimate in subgroups of PD-L1 CPS1 ( A ), PD-L1 CPS≥1 ( B ), PD-L1 CPS≥10 ( C ), and subgroup analysis ( D ). Source data are provided as a Source data file.
算法:legacy-0.5.0引擎:enhanced-linux
No curves extracted
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | failed | 待验证 | 0 | 2026-07-23T16:50:56+00:00 |